CROs/Service Providers

ICON, TriNetX partner

Monday, October 31, 2016

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has further improved its feasibility, protocol optimization and patient recruitment capabilities through the use of TriNetX.

[Read More]

Q2 Solutions, Illumina collaborate, enhance companion diagnostics capabilities

Monday, October 31, 2016

Q2 Solutions, a global clinical trials laboratory services organization, has announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q2 Solutions—EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays. The expansion of Q2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

[Read More]

FMD K&L merged with iMEDGlobal

Monday, October 24, 2016

FMD K&L and iMEDGlobal  have entered into a merger agreement. FMD K&L is a privately owned CRO with headquarters in the U.S. and China. iMEDGlobal is a privately owned CRO with headquarters in the U.S. and with main delivery centers in India and the Philippines.

[Read More]

Lovelace Biomedical launches as preclinical CRO

Monday, October 24, 2016

Lovelace Biomedical, a not-for-profit preclinical contract research organization, has launched and offers toxicology, pharmacology and other services to pharmaceutical and biotechnology companies. It will partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, with services and expertise spanning the fields of respiratory disease, infectious disease, gene therapy, neuroscience, alternative tobacco products and medical countermeasures, as well as drug discovery and others.

[Read More]

Premier Research receives Metalmark Capital growth investment

Tuesday, October 18, 2016

Premier Research, a middle-market CRO that provides comprehensive clinical development, analytic and support services to pharmaceutical, biotech and medical device customers worldwide, will receive a growth investment from Metalmark Capital, a New York-based private equity firm, which acquired its position from Indigo Capital, a long-established, independently-owned investment firm based in London.

[Read More]

Thermo Fisher Scientific launches new Pharmacoscan solution

Monday, October 17, 2016

To meet the growing demand for preemptive pharmacogenomic risk factor screening that may one day aid drug prescription practices, Thermo Fisher Scientific has introduced PharmacoScan Solution, a new microarray-based research tool that contains pharmacogenomic content with relevant markers involved in absorption, distribution, metabolism and excretion (ADME) pathways of commonly prescribed medicines.

[Read More]

Parexel launches active tracking service

Thursday, October 6, 2016

Parexel International, a global biopharmaceutical services organization, has launched its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites.

[Read More]